# A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

> **NCT03042910** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 38 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT03042910
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-13
- **Primary completion:** 2017-05-30
- **Final completion:** 2017-06-22
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03042910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03042910, "A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03042910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*